<DOC>
	<DOC>NCT02532647</DOC>
	<brief_summary>A prospective, double-blind, randomized, placebo and active controlled, multi-center, parallel group study comparing remimazolam to placebo, with an additional open-label arm for midazolam, in ASA Grade III and IV patients undergoing a colonoscopy for diagnostic or therapeutic reasons.</brief_summary>
	<brief_title>Efficacy and Safety of Remimazolam in ASA III and IV Patients Undergoing Colonoscopy</brief_title>
	<detailed_description />
	<mesh_term>Midazolam</mesh_term>
	<criteria>male and female patients, aged â‰¥ 18 years, scheduled to undergo a colonoscopy ASA grade III/IV patients patients with a known sensitivity to benzodiazepines, flumazenil, opioids, naloxone, or a medical condition such that these agents are contraindicated.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>